Project Grant R01HL174999
Award Date
8/12/24
Completion Date
4/30/28
Dollars Obligated
$2.4M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Charlottesville, VA, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $528,179 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Miami. The grant supports research to investigate whether extracellular vesicles mediate the systemic effects of ischemia training on monocyte reprogramming, and to determine if regulation of the DHCR24 enzyme in myeloid cells impacts limb perfusion, function, and arteriogenesis in peripheral arterial disease. The research...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $771,750 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, Los Angeles (UCLA) to investigate the role of macrophages in regulating cardiac muscle metabolism after myocardial infarction. The project aims to shed novel insights into how macrophages recruited to the infarcted heart disrupt cardiac muscle metabolism and lead to decreased NAD pools, which play a critical...
The National Heart Lung and Blood Institute (NHLBI) awarded a $1,547,467 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The Ohio State University to conduct research on the genetic regulation of inflammation resolution following myocardial infarction. The 5-year project aims to elucidate the impact of genetic variations in T regulatory cell CD39 expression on cardiac inflammation and healing after a heart attack. The research will leverage murine models and human patient...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,991.40 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Arkansas. The grant, effective January 2, 2025 through December 31, 2027, will support the development of microphysiological systems to investigate molecular pathways and cardiomyocyte function in response to hypoxic cardiac injury associated with myocardial infarction and ischemia-reperfusion injury. The project aims to...
This $506,984 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate the role of the LRP1 gene in the development of congenital heart disease (CHD). The primary objectives are to: Examine the deployment and migration of cardiac neural crest cells (CNCCs) and their dependence on LRP1 using in vitro and in vivo cell lineage fate mapping analysis. Investigate the cellular and molecular...
This $1,102,500 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research at the University of California, Los Angeles (UCLA) to address persistent problems in the field of intravascular triglyceride metabolism. The key focus areas include: Identifying sequences in apolipoprotein A5 (apoA5) that are important for suppressing the activity of the ANGPTL3/8 complex, and using that knowledge...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $874,792 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Vanderbilt University Medical Center (VUMC). The award, effective July 15, 2024 through June 30, 2028, will support research to: (1) identify new genetic variants associated with residual atherosclerotic cardiovascular disease (ASCVD) risk in patients on treatment to lower LDL-cholesterol...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $243,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Cincinnati's Sponsored Research Services Division. The grant will fund a 2-year project to engineer advanced RNA biodevices that leverage CRISPR and ADAR gene-editing technologies. The goal is to improve the efficiency and specificity of converting resident cardiac fibroblasts into functional cardiomyocytes, in order to boost...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $739,236 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the Childrens Hospital Medical Center in Cincinnati, OH. The grant supports research to elucidate the cellular mechanisms underlying sirolimus insensitivity in lymphangioleiomyomatosis (LAM), a rare and destructive lung disease. Key objectives include identifying molecular determinants of sirolimus insensitivity, evaluating the role of YAP-WNT pathways, and...
The National Heart Lung and Blood Institute (NHLBI) awarded a $989,908 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to the Board of Regents of Nevada System of Higher Education, doing business as the University of Nevada, Las Vegas (UNLV). The 4-year grant, effective January 1, 2025, aims to improve the efficacy of cell-based cardiac repair by examining whether treating mesenchymal stem cells (MSCs) with recombinant Wnt11 (Rwnt11) can enhance their ability to repair...